Research Summary: Targeting KRAS mutations in lung cancer

Grant Recipient: Dr. Frank J. Slack
Title of Project: Targeting KRAS mutations in lung cancer
Sponsoring Institution:
Yale University, New Haven, CT

Lung cancer is the number one cause of cancer deaths in the US, and new approaches to allow better treatments are critical to change this fact. In this proposal we are studying a recently discovered KRAS mutation, called the KRAS-variant, which is found in over 20% of non-small cell lung cancer (NSCLC) patients, and has been shown to predict a patient’s response to cancer treatment. Answering the questions proposed in this grant to confirm the role of the KRAS-variant to direct cancer therapy for lung cancer patients, and as a potential future target for therapy, has the potential to dramatically and immediately decrease death from NSCLC. The discovery of the KRAS-variant and its application in lung cancer represent a significant advance in personalized cancer therapy.